ストックスクリーナーアプリを入手
90.42
1.62%
-1.49
アフターアワーズ：
90.42
前日終値:
$91.91
開ける：
$90.62
24時間の取引高:
2.07M
Relative Volume:
1.65
時価総額：
$10.66B
収益：
$2.77B
当期純損益:
$286.61M
株価収益率:
38.48
EPS:
2.35
ネットキャッシュフロー:
$524.11M
1週間 パフォーマンス:
+1.22%
1か月 パフォーマンス:
-4.48%
6か月 パフォーマンス:
-22.15%
1年 パフォーマンス:
-16.54%
1日の値動き範囲:
$89.47
$91.64
1週間の範囲:
$89.47
$93.57
52週間の値動き範囲:
$88.01
$129.50
Revvity Inc Stock (RVTY) Company Profile
RVTY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
90.42 | 10.53B | 2.77B | 286.61M | 524.11M | 2.35 |
|
TMO
Thermo Fisher Scientific Inc
|
402.82 | 148.60B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.90 | 132.07B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
513.36 | 40.34B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
111.92 | 30.82B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
140.33 | 23.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-01 | アップグレード | UBS | Neutral → Buy |
| 2025-01-10 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-15 | アップグレード | Barclays | Equal Weight → Overweight |
| 2024-08-28 | 開始されました | Wells Fargo | Equal Weight |
| 2024-07-08 | 開始されました | Leerink Partners | Outperform |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2024-01-16 | ダウングレード | UBS | Buy → Neutral |
| 2024-01-04 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-07-19 | 開始されました | Raymond James | Outperform |
| 2023-05-23 | 再開されました | Goldman | Buy |
すべてを表示
Revvity Inc (RVTY) 最新ニュース
Insider Sell: Michelle Mcmurry-heath Sells 600 Shares of Revvity Inc (RVTY) - GuruFocus
Does The Market Have A Low Tolerance For Revvity, Inc.'s (NYSE:RVTY) Mixed Fundamentals? - Yahoo
Shareholders in Revvity (NYSE:RVTY) are in the red if they invested three years ago - simplywall.st
Revvity Inc (RVTY) Shares Up 3.52% on May 27 - GuruFocus
RVTY Stock Falls Despite the Latest Launch of Automated Instrument - MSN
Revvity’s EUROIMMUN unveils new fully automated instrument for specialty testing - SelectScience
Enhancing Laboratory Efficiency with Revvity's IDS i20™ Platform - Lab Manager
Is Wall Street Bullish or Bearish on Revvity Stock? - inkl
Is Wall Street Bullish Or Bearish On Revvity Stock? - Barchart.com
Revvity (RVTY) Receives Affirmed Buy Rating with Promising Outlo - GuruFocus
Revvity (RVTY) Receives Affirmed Buy Rating with Promising Outlook | RVTY Stock News - GuruFocus
Sustainable chemistry in India fueling growth with digital and AI innovation: Revvity Signals - Indian Chemical News
Revvity announces launch of new fully automated instrument for specialty testing - BioSpectrum India
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for S - GuruFocus
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing | RVTY Stock News - GuruFocus
Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing - Business Wire
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity Signals Software Inc. v. Cloud Software Group Inc. - Cornerstone Research
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight - GlobeNewswire Inc.
Shareholders Will Be Pleased With The Quality of Revvity's (NYSE:RVTY) Earnings - Yahoo
Revvity at Bank of America 2025 Healthcare Conference: Navigating Tariffs and Growth - Investing.com
Revvity To Present At Bank Of America Global Healthcare Conference 2025; Webcast At 12:20 PM ET - Nasdaq
Revvity beats quarterly estimates on steady demand for medical equipment - MSN
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know - Yahoo Finance
RVTY Q1 Earnings Call: Resilient Performance Amid Academic and Tariff Headwinds, Software and Diagnostics Shine - Yahoo Finance
Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy (NYSE:RVTY) - Seeking Alpha
High Content Screening Market Global Forecasts 2025-2030 - GlobeNewswire
High Content Screening Market Global Forecasts 2025-2030 with Danaher, Revvity, BD, Carl Zeiss, Merck, and Thermo Fisher Scientific Dominating the $2.19 Billion Market - Yahoo Finance
Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook - MSN
Revvity Announces Financial Results for the First Quarter of 2025 - ADVFN
UBS Upgrades Revvity (BMV:RVTY) - Nasdaq
UBS Upgrades Revvity (BIT:1RVTY) - Nasdaq
UBS lifts Revvity stock rating to Buy, cuts price target to $115 - Investing.com Australia
UBS Upgrades Revvity (LSE:0KHE) - Nasdaq
UBS Upgrades Revvity (RVTY) - Nasdaq
UBS Boosts Revvity (RVTY) Rating to Buy Amid Growth Prospects | - GuruFocus
UBS lifts Revvity stock rating to Buy, cuts price target to $115 By Investing.com - Investing.com South Africa
UBS Upgrades Revvity to Buy from Neutral, Cuts Price Target to $115 From $145 - marketscreener.com
UBS Boosts Revvity (RVTY) Rating to Buy Amid Growth Prospects | RVTY Stock News - GuruFocus
Revvity to Present at Upcoming Investor Conferences | RVTY Stock News - GuruFocus
KeyBanc Adjusts Revvity's Price Target to $135 From $145 - marketscreener.com
Revvity CEO and CFO to Share Strategic Vision at BofA and Goldman Sachs Healthcare Conferences - Stock Titan
Revvity Reports Strong Q1 2025 Financial Results - TipRanks
Revvity reaffirms 2025 guidance with $4.90-$5 EPS target amid robust software growth - MSN
Stifel maintains Revvity stock Hold rating, $120 target By Investing.com - Investing.com Canada
Biotech Firm Revvity Reports Better-Than-Expected Earnings - MSN
Stifel maintains Revvity stock Hold rating, $120 target - Investing.com
Revvity Inc (RVTY) 財務データ
収益
当期純利益
現金流量
EPS
0.78%
1.71%
大文字化:
|
ボリューム (24 時間):